Adds niraparib to maintenance immunotherapy in small cell lung cancer
Tests adding niraparib to anti-PD-L1 maintenance in adults with extensive small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Key facts
- Where
- A Coruña, Jaén, and Majadahonda, SpainSee the 3 sites
- Phase
- Phase 2
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Hospital Universitario de JaénJaén, SpainTaking people
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ETOP IBCSG Partners Foundation
- Trial code
- NCT05718323EU 2022-502092-33-00
- Record updated
- 29 May 2026
- Original description
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.Read full original descriptionShow less
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
Inclusion: Written IC part 1: for SLFN11-screening must be signed and dated by the patient and the investigator prior to sending any tumour material to the central laboratory; Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification); Availability of FFPE tumour tissue for screening; Written IC part 2: for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention; High SLFN11-expression on FFPE tumour material:; SLFN11-expression is determined at the central screening laboratory in Basel. Overexpression is defined as detectable protein expression by IHC in ≥20% of tumour cells; Patients must have received standard first-line chemo-immunotherapy, consisting of 4 cycles of platinum-etoposide chemotherapy in combination with an anti-PD-L1 antibody (atezolizumab or durvalumab). Patients who started the immunotherapy at chemotherapy cycle 2 are eligible; ED-SCLC must not have progressed during or after standard chemo-immunotherapy (as per RECIST v1.1); Patients must be candidates for ongoing maintenance treatment with immune-checkpoint inhibition; Adequate haematological function:; Adequate renal function:; Adequate liver function:; ECOG PS 0-2; Age ≥18 years; Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 4 weeks before enrolment and within 3 days before treatment start.
Exclusion: Any serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) which in the opinion of the investigator would compromise the patient's ability to complete the trial or interfere with the evaluation of the efficacy and safety of the protocol treatment; Prior Reversible Encephalopathy Syndrome (PRES); Treated with live vaccine within 30 days before enrolment; Any clinically active cancer, other than SCLC Exception: malignancies with negligible risk of metastases or death (e.g. 5-year OS rate of >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer. Hormonal therapy for non-metastatic prostate or ductal carcinoma in situ is allowed; Consolidating thoracic radiotherapy. Palliative radiotherapy to the brain or to bones is allowed; History of idiopathic pulmonary fibrosis, organising pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; Any lung disease requiring systemic steroids in doses of >10 mg prednisolone (or equivalent dose of other steroid); Inadequately controlled hypertension, defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >95 mmHg; The patient must be considered stable and hypertension medically controlled; History of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML); Severe renal or hepatic impairment; Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach and/or bowels; Hypersensitivity to niraparib or any of its excipients (e.g., tartrazine); Symptomatic brain metastases; Women who are pregnant or in the period of lactation; Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the trial and within the required timelines after last dose of niraparib treatment; Judgment by the investigator that the patient is unlikely to comply with trial procedures, restrictions and requirements.